CORRECTED - CORRECTED-(Aug 31)-UPDATE 1-Pozen says FDA accepts Vimovo NDA
(Corrects second paragraph in Aug. 31 story to clarify the drug Vimovo contains an immediate release form of AstraZeneca's esomeprazole, not the enteric-coated formulation found in Nexium)
* Pozen to get $10 mln payment from AstraZeneca
* Shares rise 11 pct
Aug 31 (Reuters) - Pozen Inc (POZN.O) said U.S. health regulators have accepted a marketing application for its experimental pain drug Vimovo, triggering a $10 million milestone payment from AstraZeneca (AZN.L) to Pozen.
The drug Vimovo is a fixed-dose combination of the enteric-coated anti-inflammatory naproxen and an immediate release formulation of AstraZeneca's esomeprazole.
Pozen shares were up 9 percent to $7.03 in morning trade Monday on Nasdaq. They touched a high of $7.18 in early trade. (Reporting by Shailesh Kuber in Bangalore; Editing by Gopakumar Warrier)










